Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 78

1.

Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer.

Lee KH, Kim HO, Yoo CH, Son BH, Park YL, Cho YK, Kim H, Han WK.

Korean J Gastroenterol. 2012 Mar;59(3):218-23.

2.

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B; EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG)..

Ann Oncol. 2012 Oct;23(10):2619-26.

3.

Minimally invasive evaluation and treatment of colorectal liver metastases.

Gueorguiev AL, Mackey R, Kowdley GC, Esquivel J, Cunningham SC.

Int J Surg Oncol. 2011;2011:686030. doi: 10.1155/2011/686030.

4.

Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience.

Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, Sheetz M, Gamblin TC.

Int J Surg Oncol. 2011;2011:571261. doi: 10.1155/2011/571261.

5.

Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.

Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, Bekaii-Saab T.

Clin Colorectal Cancer. 2012 Sep;11(3):195-9. doi: 10.1016/j.clcc.2011.12.002.

6.

Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.

Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S, Benea G.

Anticancer Res. 2011 Dec;31(12):4581-7.

PMID:
22199334
7.

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.

Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S.

World J Surg Oncol. 2011 Aug 6;9:86. doi: 10.1186/1477-7819-9-86. Erratum in: World J Surg Oncol. 2011;9:120.

8.

Liver-directed therapies in colorectal cancer.

Alsina J, Choti MA.

Semin Oncol. 2011 Aug;38(4):561-7. doi: 10.1053/j.seminoncol.2011.05.010. Review.

PMID:
21810515
9.

Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer.

Bouchahda M, Lévi F, Adam R, Rougier P.

Eur J Cancer. 2011 Dec;47(18):2681-90. doi: 10.1016/j.ejca.2011.06.037. Review.

PMID:
21783358
10.

Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, Owen R.

Cancer Treat Rev. 2012 Feb;38(1):54-62. doi: 10.1016/j.ctrv.2011.05.002. Review.

PMID:
21726960
11.

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?

Burak KW.

Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300. Review. No abstract available.

PMID:
21548474
12.

Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases.

Sgouros J, Cast J, Garadi KK, Belechri M, Breen DJ, Monson JR, Maraveyas A.

World J Gastrointest Oncol. 2011 Apr 15;3(4):60-6. doi: 10.4251/wjgo.v3.i4.60.

13.

Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.

Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P.

J Vasc Interv Radiol. 2011 Jun;22(6):780-6. doi: 10.1016/j.jvir.2011.02.023.

PMID:
21515072
14.

Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?

Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N, Lartigau E, Mirabel X.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e39-47. doi: 10.1016/j.ijrobp.2010.12.047.

PMID:
21377292
15.

A review of the treatment of chronic hepatitis C virus infection in cirrhosis.

Vezali E, Aghemo A, Colombo M.

Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1. Review.

PMID:
21316532
16.

Hepatocellular carcinoma: current management and perspectives for the future.

Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J.

Ann Surg. 2011 Mar;253(3):453-69. doi: 10.1097/SLA.0b013e31820d944f. Review.

PMID:
21263310
17.

Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis.

Nishiofuku H, Tanaka T, Aramaki T, Boku N, Inaba Y, Sato Y, Matsuoka M, Otsuji T, Arai Y, Kichikawa K.

Clin Colorectal Cancer. 2010 Dec;9(5):305-10. doi: 10.3816/CCC.2010.n.044. Erratum in: Clin Colorectal Cancer. 2011 Mar 1;10(1):7.

PMID:
21208845
18.

Review of the processes for FDA oversight of drugs, medical devices, and combination products.

Sweet BV, Schwemm AK, Parsons DM.

J Manag Care Pharm. 2011 Jan-Feb;17(1):40-50. Review. No abstract available.

19.

Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.

Chua TC, Bester L, Saxena A, Morris DL.

J Cancer Res Clin Oncol. 2011 May;137(5):865-73. doi: 10.1007/s00432-010-0948-y.

PMID:
20859640
20.

Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol.

Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI, Soulen MC.

Cancer. 2011 Jan 15;117(2):343-52. doi: 10.1002/cncr.25387.

Items per page

Supplemental Content

Support Center